Onco Actu du 31 mars 2016

	2. Etiologie
Common diabetes drug raises risk of developing cancer [The Telegraph] The anti-diabetic drug pioglitazone raises the risk of bladder cancer by 63 per cent, researchers found.
	3.1 Tabac
When is a smoker an adult? Why we shouldn’t raise the legal smoking age to 21 [The Conversation] Juvenile smoking suppression acts have existed in state legislation since the early years of last century. But these long-standing laws that can fine retailers from selling tobacco to those under 18 have not stopped 5.1% of 12- to 17-year-olds from smoking in the most recent national survey.
	4.2 Dép., diag. & prono. - Génome
Children with cancer to get new gene test [The Institute of Cancer Research] The initiative is the first stage of a wider programme which eventually aims to provide testing for all children with solid tumours in the UK, and to direct them into clinical trials targeting particular mutations within their tumours.
'Exciting' new genetic test for child cancer patients [BBC News] The new test analyses changes in 81 different cancer genes. Scientists say it should lead to "a more level playing field", and accelerate children's access to important new drugs.
	4.5 Dép., diag. & prono. - Colorectal
Reminder letter encourages more people to take bowel scope screening test [Cancer Research UK] The research was carried out with people previously invited for bowel scope screening in the London Boroughs of Brent and Harrow where fewer people than the national average accept their bowel scope invitation.
	5.12 Immunothérapies
Sanofi Genzyme helps cancer biotech ImmuneXcite close $8.6M financing round [FierceBiotech] By attaching a fungal sugar known as beta-1,6-glucan to antibodies that seek out and bind to tumor cells, mAbXcite therapies recruit neutrophils, the first responders of the immune system, to cancer cells. The neutrophils then recruit other immune cells, including T-cells, to mount an immune attack.
	5.12.2 Immunothérapies - CAR-T
Exploring the assessment and appraisal of regenerative medicines and cell therapy products [NICE] In modelling cost-effectiveness, an estimate of the acquisition cost of CAR T-cell therapy was needed. In the absence of a commercially available product and published price, a price was assumed such that the economic analysis would give a result close to NICE’s cost effectiveness threshold.
	5.2 Pharma
GSK Reaffirms Its Commitment To Oncology Research But The Strategy Is Unclear [Forbes] Without oncology drugs to sell, presumably the oncology sales force has moved on to other products. If and when the new cancer drugs reach patients and physicians, will they be reunited or will the sales team need to be rebuilt?
	5.2.1 Pharma - Partenariats
Boehringer Ingelheim Venture Fund invests in Amal Therapeutics to develop novel therapeutic colorectal cancer vaccine [Boehringer Ingelheim] Amal Therapeutics is a Swiss biotech company developing and progressing therapeutic cancer vaccines. The company will use the funds to progress the preclinical development of its lead vaccine (ATP124) for colorectal cancer and to further develop its KISIMA technology platform for therapeutic tumor vaccination.
	5.2.3 Pharma - économie
The price of health: the cost of developing new medicines [The Guardian] Why is the process so inefficient? “The predictive power of the biology we do in research labs is relatively poor,” says Solari. “So when we test hypotheses in the clinic, they fail more often than they succeed. A big part of the problem is that animal models are not particularly predictive of human efficacy.”
	5.3 Traitements - FDA, EMA,...
FDA Review Times Steadily Decreasing, Report Finds [RAPS] Back in 2009, FDA was averaging 21 months for reviewing new molecular and biologic entities, but five years later, that average has been cut by more than half to nine months in 2014.
European Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients [BMS] Opdivo has potential to become first PD-1 inhibitor approved in a hematological malignancy in European Union.
	5.3.4 Traitements - AMM (FDA, EMA)
FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow [FDA] The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT).
	5.4 Traitements - Economie
Only Two Out of Ten Drugs? Really? [In the Pipeline] This business is hard enough already without making it look even harder than it is. BIO and the others using this number should back off of it – would they really like to try to document it? Didn’t think so.
Prominent doctors group supports controversial moves to lower drug prices [STAT] The pharmaceutical industry regularly maintains that pricing funds needed investment and has previously argued against some of the proposals embraced by the American College of Physicians.
	6.10 Politiques
Curing Cancer Is Within Reach [Bloomberg] With the right partnerships, we can bolster the incredible work that is already occurring among immunologists, geneticists and other scientists with new innovations from the technology sector.
Cancer And The Presidency: Why This CEO Says Each Candidate Needs A Plan [Forbes] The site has launched a Twitter campaign, and Berman recently published an editorial on Fox News’ website suggesting that the candidates should be less focused on the threat of gun violence in the U.S. and other hot-button issues and more worried about terrorist cancer cells that could be lurking undetected in our bodies.